MEGIN is excited to be among the delegate of pioneering HealthTech companies heading to Texas as part of the first major US trade mission organized by the Association of British HealthTech Industries (ABHI) since the COVID-19 pandemic.
The visit marks the launch of a series of ABHI-led trade missions across the US as part of its flagship US Accelerator program.
MEGIN joins twenty-eight of the UK’s leading HealthTech innovators heading stateside to strengthen trading relationships. The week-long missions – exclusive to members of the ABHI US Accelerator – aim to provide participants with access to senior leaders, clinicians and procurement teams from world-class hospital systems across the country, supporting them in engaging the right stakeholders and gaining valuable market insight.
Taking place from 27 March to 1 April, the Texas visit will provide a prime opportunity to forge more personal and lasting ties with the network of leaders and hospital systems ABHI has cultivated in Texas over the years and aims to generate further demand for UK-developed products.
The cohort of companies will be showcasing a range of UK HealthTech products and solutions as part of the mission, and to further demonstrate the strengths of the UK, a number of key clinical and academic figures will be joining the mission.
To enhance peer-to-peer learning and further strengthen international collaboration between respective health systems, UK leaders joining the delegation include Professor Tony Young, National Clinical Lead for Innovation at NHS England, Professor David Jayne, Professor of Surgery at the University of Leeds & Co-Director of the Leeds Centre for HealthTech Innovation (CHTI), and Dr Neville Young, Director of Enterprise & Innovation at the Academic Health Science Network.
Throughout the week, members will participate in a series of meetings, networking events and introductions across Austin, Fort Worth, Dallas, and Houston – four of the biggest cities in Texas.
“MEGIN is delighted to be among the twenty-eight UK HealthTech pioneers joining the ABHI trade mission to Texas. The state is currently home to three MEGIN devices, and we hope to continue expansion in the region. We aim to build greater MEG awareness on this trip, and how our non-invasive technology can support clinical outcomes in epilepsy through data allowing for more informed decision-making, as well as MEG’s utilization in research. We look forward to meeting clinical leaders face-to-face and furthering our mission to strengthen relationships with key stakeholders in the US,” said Gabriele Richardson, Head of Marketing and delegate from MEGIN on the trade mission.
Centered in Texas, the ABHI US Accelerator is delivered in partnership with the Dell Medical School, one of the United States’ most pioneering academic institutions, based at the University of Texas, in Austin. Using the state as a springboard to other key states, the program offers nationwide support, drawing on the relationships and connections built up across the US.
Texas is renowned as an economic powerhouse. It has the second largest GDP of any US State at 1.7 trillion dollars and were it a sovereign country, would be ranked as the 12th largest economy in the world by GDP.
Throughout the year, MEGIN will also take part in missions to other key states, including California, Tennessee, Minnesota, and Florida – a major state for HealthTech companies entering the US Market – and New York, another East Coast powerhouse.
Paul Benton, Managing Director, International, ABHI commented: “With regional headquarters of some of the country’s largest healthcare providers located in the State, Texas provides tangible opportunities to UK companies and acts as the perfect springboard for them to access the wider United States. Our mission targets senior leaders across many of the main hospital systems in the State and offers unprecedented access to key decision makers and leaders. We are keen to be heading back to Texas following a brief hiatus, and we look forward to supporting our companies in exploring collaborative opportunities in the US and strengthening their partnerships.”
For more information, visit: https://www.abhi.org.uk/international/abhi-us-accelerator/
ABHI is the UK’s leading industry association for health technology (HealthTech).
ABHI supports the HealthTech community to save and enhance lives. Members, including both multinationals and small and medium sized enterprises (SMEs), supply products from syringes and wound dressings to surgical robots and digitally enhanced technologies. We represent the industry to stakeholders, such as the government, NHS and regulators. HealthTech plays a key role in supporting delivery of healthcare and is a significant contributor to the UK’s economic growth. HealthTech is the largest employer in the broader Life Sciences sector, employing 138,100 people in 4,140 companies, with a combined turnover of £27.6bn. The industry has enjoyed growth of around 5% in recent years. ABHI’s 320 members account for approximately 80% of the sector by value.
MEGIN is a neuroscience technology company based in Helsinki, Finland. The company is focused on developing innovative solutions for functional brain mapping for the presurgical evaluation of epilepsy, brain tumors or other lesions of the brain. For over 30 years, MEGIN has been the global leader in magnetoencephalography (MEG) technology. The TRIUX™ neo provides a non-invasive, real-time view of patient-specific neural activity with millimeter accuracy and millisecond resolution, providing the most precise information currently available on the market.
Copyright 2022 © MEGIN – TRIUX™ neo is available for sale in the European Union, UK, Japan, Canada, the United States, as well as certain other countries. In other geographical areas, contact your local MEGIN representative. TRIUX™ neo is approved for use to non-invasively localize regions of epileptic activity within the brain and, in conjunction with other diagnostic data, in neurosurgical planning. All other applications are research in nature.